OBJECTIVES:
Primary
* Determine the efficacy of this regimen by the measurement of objective response rate (RECIST criteria).
Secondary
* Determine the toxicity of this regimen.
* Evaluate the duration of tumor response.
* Determine the duration and rate of tumor control.
* Determine the rate of secondary resectability of hepatic metastases.
* Evaluate progression-free survival
* Determine rate of progression of the tumor.
* Determine overall survival.
OUTLINE: This is a multicenter study.
Patients receive cetuximab IV over 1 hour, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours. Patients also receive oxaliplatin by hepatic arterial infusion over 2 hours. Treatment continues for at least 3 months in the absence of disease progression or unacceptable toxicity.
